Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $65

Benzinga Newsdesk www.benzinga.com Negative 54.0%

Neg 54% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $475 to $65.